Research project

Evaluation of immunotherapeutic approaches to keratinocyte carcinoma treatment in preclinical models

The demand for effective non-invasive treatments is pressing in cases of advanced keratinocyte cancers that are unresectable. We aim at investigating innovative therapies designed to reactive the immune systems to combat the cancer.

Over the past decade, immunotherapy has demonstrated significant efficacy across various cancer types. The project aims at assessing novel immunotherapies and understand their underlying mechanisms. This includes investigating how specific immune cells interact with the tumor microenvironment, utilizing advanced techniques.

An important component of the project is to establish a refined preclinical model of keratinocyte cancer, which may pave the way for advancements in the development of therapies specifically tailored to keratinocyte. The overall objective is to contribute to the evolving landscape of immunotherapies for keratinocyte cancers.

Researcher

MSc. Molecular Biomedicine, Martin Wiinberg

Project supervisors

Supervisor: Professor Thomas Lars Andresen, PhD

Co-supervisor: Professor Merete Hædersdal, MD, PhD, DMSc

Co-supervisor: Senior Researcher Uffe Høgh Olesen, PhD

Project period

Year 2020 – 2024

Project collaborators

Bispebjerg Hospital, Department of Dermatology

The Danish Research Center for Skin Cancer

Financing

DTU

SCIN CAG

Selected publications

Olesen UH, Wiinberg M, Lerche CM, Jæhger DE, Andresen TL, Haedersdal M. Anti-PD-1 Therapy with Adjuvant Ablative Fractional Laser Improves Anti-Tumor Response in Basal Cell Carcinomas. Cancers 2021;13(24):6326.

Christensen RL, Wiinberg M, Lerche CM, Demehri S, Olesen UH, Haedersdal M. Anti-PD-1 immunotherapy with adjuvant ablative fractional laser displays increased tumour clearance of squamous cell carcinoma, a murine study. Exp Dermatol. 2024; 33:e15013.

Related research projects